Indeed, the CD4/NPM-ALK approach also gave rise to two other transgenic lines, one that produced plasmacytomas or thymic tumours, but another that exclusively develops thymic T-cell lymphomas [84]; the reasons for these disparate phenotypes from the same round of microinjection are not immediately apparent and might reflect previously discussed concepts. The gene discussed is CD4; the disease is plasmacytoma.